Silibinin and Colorectal Cancer Chemoprevention: a Comprehensive Review on Mechanisms and Efficacy

Overview

Journal J Biomed Res

Specialty General Medicine

Date 2016 Aug 2

PMID 27476880

Citations 9

Authors

Komal Raina

Sushil Kumar

Deepanshi Dhar

Rajesh Agarwal

Affiliations

Soon will be listed here.

Abstract

Globally, the risk of colorectal cancer (CRC) as well as the incidence of mortality associated with CRC is increasing. Thus, it is imperative that we look at alternative approaches involving intake of non-toxic natural dietary/non-dietary agents, for the prevention of CRC. The ultimate goal of this approach is to reduce the incidence of pre-neoplastic adenomatous polyps and prevent their progression to more advanced forms of CRC, and use these natural agents as a safe intervention strategy during the clinical course of this deadly malignancy. Over the years, pre-clinical studies have shown that silibinin (a flavonolignan isolated from the seeds of milk thistle, ) has strong preventive and therapeutic efficacy against various epithelial cancers, including CRC. The focus of the present review is to provide a comprehensive tabular summary, categorically for an easy accessibility and referencing, pertaining to the efficacy and associated mechanisms of silibinin against CRC growth and progression.

Citing Articles

Flavonoids and Flavonoid-Based Nanopharmaceuticals as Promising Therapeutic Strategies for Colorectal Cancer-An Updated Literature Review.

Smeu A, Marcovici I, Dehelean C, Dumitrel S, Borza C, Lighezan R Pharmaceuticals (Basel). 2025; 18(2).

PMID: 40006045 PMC: 11858883. DOI: 10.3390/ph18020231.

A Review of Nutraceuticals in Cancer Cachexia.

Caeiro L, Gandhay D, Anderson L, Garcia J Cancers (Basel). 2023; 15(15).

PMID: 37568700 PMC: 10417577. DOI: 10.3390/cancers15153884.

Silibinin exhibits anti-tumor effects in a breast cancer stem cell model by targeting stemness and induction of differentiation and apoptosis.

Firouzi J, Sotoodehnejadnematalahi F, Shokouhifar A, Rahimi M, Sodeifi N, Sahranavardfar P Bioimpacts. 2022; 12(5):415-429.

PMID: 36381630 PMC: 9596878. DOI: 10.34172/bi.2022.23336.

Chiral Flavonoids as Antitumor Agents.

Pinto C, Cidade H, Pinto M, Tiritan M Pharmaceuticals (Basel). 2021; 14(12).

PMID: 34959668 PMC: 8704364. DOI: 10.3390/ph14121267.

Anticancer Potential of Silibinin Loaded Polymeric Nanoparticles against Breast Cancer Cells: Insight into the Apoptotic Genes Targets.

Pourgholi A, Dadashpour M, Mousapour A, Firouzi Amandi A, Zarghami N Asian Pac J Cancer Prev. 2021; 22(8):2587-2596.

PMID: 34452574 PMC: 8629447. DOI: 10.31557/APJCP.2021.22.8.2587.

References

Ward R, Dirks P . Cancer stem cells: at the headwaters of tumor development. Annu Rev Pathol. 2007; 2:175-89. DOI: 10.1146/annurev.pathol.2.010506.091847. View

Kaur M, Velmurugan B, Tyagi A, Deep G, Katiyar S, Agarwal C . Silibinin suppresses growth and induces apoptotic death of human colorectal carcinoma LoVo cells in culture and tumor xenograft. Mol Cancer Ther. 2009; 8(8):2366-74. PMC: 2728169. DOI: 10.1158/1535-7163.MCT-09-0304. View

Sangeetha N, Aranganathan S, Nalini N . Silibinin ameliorates oxidative stress induced aberrant crypt foci and lipid peroxidation in 1, 2 dimethylhydrazine induced rat colon cancer. Invest New Drugs. 2009; 28(3):225-33. DOI: 10.1007/s10637-009-9237-5. View

Dalerba P, Dylla S, Park I, Liu R, Wang X, Cho R . Phenotypic characterization of human colorectal cancer stem cells. Proc Natl Acad Sci U S A. 2007; 104(24):10158-63. PMC: 1891215. DOI: 10.1073/pnas.0703478104. View

Ravichandran K, Velmurugan B, Gu M, Singh R, Agarwal R . Inhibitory effect of silibinin against azoxymethane-induced colon tumorigenesis in A/J mice. Clin Cancer Res. 2010; 16(18):4595-606. PMC: 3000041. DOI: 10.1158/1078-0432.CCR-10-1213. View

Raina K, Agarwal R . Promise and potential of silibinin in colorectal cancer management: what patterns can be seen?. Future Oncol. 2013; 9(6):759-61. PMC: 3935325. DOI: 10.2217/fon.13.51. View

Raina K, Agarwal C, Agarwal R . Effect of silibinin in human colorectal cancer cells: targeting the activation of NF-κB signaling. Mol Carcinog. 2011; 52(3):195-206. PMC: 3563833. DOI: 10.1002/mc.21843. View

Ting H, Deep G, Agarwal R . Molecular mechanisms of silibinin-mediated cancer chemoprevention with major emphasis on prostate cancer. AAPS J. 2013; 15(3):707-16. PMC: 3691417. DOI: 10.1208/s12248-013-9486-2. View

Ricci-Vitiani L, Fabrizi E, Palio E, De Maria R . Colon cancer stem cells. J Mol Med (Berl). 2009; 87(11):1097-104. DOI: 10.1007/s00109-009-0518-4. View

10.

Sangeetha N, Nalini N . Silibinin modulates caudal-type homeobox transcription factor (CDX2), an intestine specific tumor suppressor to abrogate colon cancer in experimental rats. Hum Exp Toxicol. 2014; 34(1):56-64. DOI: 10.1177/0960327114530741. View

11.

Verschoyle R, Greaves P, Patel K, Marsden D, Brown K, Steward W . Evaluation of the cancer chemopreventive efficacy of silibinin in genetic mouse models of prostate and intestinal carcinogenesis: relationship with silibinin levels. Eur J Cancer. 2008; 44(6):898-906. DOI: 10.1016/j.ejca.2008.02.020. View

12.

Woo S, Min K, Kim S, Park J, Kim D, Chun K . Silibinin induces apoptosis of HT29 colon carcinoma cells through early growth response-1 (EGR-1)-mediated non-steroidal anti-inflammatory drug-activated gene-1 (NAG-1) up-regulation. Chem Biol Interact. 2014; 211:36-43. DOI: 10.1016/j.cbi.2014.01.004. View

13.

Velmurugan B, Singh R, Tyagi A, Agarwal R . Inhibition of azoxymethane-induced colonic aberrant crypt foci formation by silibinin in male Fisher 344 rats. Cancer Prev Res (Phila). 2009; 1(5):376-84. PMC: 2612598. DOI: 10.1158/1940-6207.CAPR-08-0059. View

14.

Raina K, Agarwal C, Wadhwa R, Serkova N, Agarwal R . Energy deprivation by silibinin in colorectal cancer cells: a double-edged sword targeting both apoptotic and autophagic machineries. Autophagy. 2013; 9(5):697-713. PMC: 3669180. DOI: 10.4161/auto.23960. View

15.

Sangeetha N, Aranganathan S, Panneerselvam J, Shanthi P, Rama G, Nalini N . Oral supplementation of silibinin prevents colon carcinogenesis in a long term preclinical model. Eur J Pharmacol. 2010; 643(1):93-100. DOI: 10.1016/j.ejphar.2010.05.060. View

16.

Derry M, Raina K, Agarwal C, Agarwal R . Identifying molecular targets of lifestyle modifications in colon cancer prevention. Front Oncol. 2013; 3:119. PMC: 3653120. DOI: 10.3389/fonc.2013.00119. View

17.

Singh R, Gu M, Agarwal R . Silibinin inhibits colorectal cancer growth by inhibiting tumor cell proliferation and angiogenesis. Cancer Res. 2008; 68(6):2043-50. DOI: 10.1158/0008-5472.CAN-07-6247. View

18.

Lin C, Chen Y, Ma H, Wang B, Chiu J, Chua S . Silibinin inhibits the invasion of IL-6-stimulated colon cancer cells via selective JNK/AP-1/MMP-2 modulation in vitro. J Agric Food Chem. 2012; 60(51):12451-7. DOI: 10.1021/jf300964f. View

19.

Velmurugan B, Gangar S, Kaur M, Tyagi A, Deep G, Agarwal R . Silibinin exerts sustained growth suppressive effect against human colon carcinoma SW480 xenograft by targeting multiple signaling molecules. Pharm Res. 2010; 27(10):2085-97. PMC: 3085838. DOI: 10.1007/s11095-010-0207-6. View

20.

Wang J, Chang C, Chiang C, Chen W, Hung S . Silibinin suppresses the maintenance of colorectal cancer stem-like cells by inhibiting PP2A/AKT/mTOR pathways. J Cell Biochem. 2012; 113(5):1733-43. DOI: 10.1002/jcb.24043. View